KymaThera, Rouge raise VC funding; Vaxcyte, Spyre do public offerings

Summary

KymaThera raised $80M in Series B funding to develop K-1728, a pan-mutant selective PI3Kα inhibitor oral medicine entering Phase 1. Vaxcyte and Spyre also completed public offerings in a biotech funding round.